Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

By Kang Byung   Kim Won   Kim Chul   Jang Geundoo   Lee Sung   Choi Yoon   Lee Dae   Kim Sang   Kim Shin   Ryu Jin-Sook   Huh Jooryung   Lee Jung   Suh Cheolwon  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 516-522

Springer Publishing Company

Access to resources Recommend Favorite

Zevalin TM: 90 Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin's Lymphoma

By  

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 341-349

Bentham Science Publishers

Access to resources Recommend Favorite

Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma

By  

Current Pharmaceutical Biotechnology, Vol. 1, Iss. 4, 2000-12 ,pp. : 303-312

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 4, 2006-12 ,pp. : 345-350

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3465-3471

Blackwell Publishing

Access to resources Recommend Favorite